Meanwhile, the research team made another attempt on predicting the O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status of GBM based on a multi-region and multi-parametric MRI radiomics model, and the results showed that combining clinical factors with radiomics features does not improve predictive performance (65). This evidence concerns the gene MGMT and glioblastoma.